US opioid manufacturers propose phase-in of class-wide REMS
This article was originally published in Scrip
Executive Summary
The manufacturers of long-acting opioids have proposed a phased-in approach to implementing a joint US risk evaluation and mitigation strategy (REMS), starting with individual product-specific medication guides before eventually shifting to a single class-wide medguide.